Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
about
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersChallenging and complex decisions in the management of the BRCA mutation carrierImproving the management of people with a family history of breast cancer in primary care: before and after study of audit-based educationA prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group studyOral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis.Hormonal contraception and risk of cancer.Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.[Hormonal contraception and breast cancer risk].Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian CancerOral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.An overview of hereditary breast and ovarian cancer syndrome.Clinical management of BRCA1 and BRCA2 mutation carriers.Risk of cancer development in relation to oral contraception.Disease-specific prospective family study cohorts enriched for familial risk.DNA stabilization by the upregulation of estrogen signaling in BRCA gene mutation carriers.Online tool to guide decisions for BRCA1/2 mutation carriers.Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutationEndometrial and ovarian cancer in lynch syndrome.Breast cancer susceptibility testing: past, present and future.Cancer risks among BRCA1 and BRCA2 mutation carriers.Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutationsManagement updates for women with a BRCA1 or BRCA2 mutation.Management of the asymptomatic BRCA mutation carrier.Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors.Cohort Profile: The Breast Cancer Prospective Family Study Cohort (ProF-SC)Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTSTriple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implicationsReproductive risk factors and oestrogen/progesterone receptor-negative breast cancer in the Breast Cancer Family Registry.Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers.Management of genetic syndromes predisposing to gynecologic cancers.Risk-benefit assessment of the combined oral contraceptive pill in women with a family history of female cancer.Impact of a paternal origin of germline BRCA1/2 mutations on the age at breast and ovarian cancer diagnosis in a Southern Swedish cohort.Oral contraceptive use in women at increased risk of breast/ovarian cancer: knowledge and attitudes.Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes.Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect
P2860
Q24654487-EC79185F-B3CA-46F3-A661-12DAADFDBE5DQ27026559-521FC4A4-3388-4115-9406-2AA7C8BBADA4Q28386892-DA94E4EE-7524-4B45-904D-8950DAD27BA9Q30431721-F74911D2-D396-4691-AB98-0D21FF5C5550Q30433319-DB794B3C-2A7F-44DD-A8F9-0C61D263A16DQ34077422-E2D9C0AA-98D8-4060-8CF3-16D89D30724CQ34120493-8F100D40-36D2-429F-B0B5-DEF1F11F9790Q34126089-07F5683A-756C-49C7-B769-9AEFA7BCE5A4Q34131588-CA6CCD6D-9344-4554-ADAA-AE4691F39B4FQ34152848-8E542DE8-08F7-4A7E-A7ED-3E77C9C01310Q34216239-93923BC9-99B2-4DD9-B795-205382FD27F0Q34305000-FBC78607-0F0A-4B7D-BFFB-DBF2C2ABDD4EQ34568554-EA0313FE-C653-491C-BE7C-1ABFF2800593Q34575924-C7A82133-F24A-4793-98DE-B0EDFBBFD326Q34662485-736E9E53-ADF4-49BE-8144-4DA3F34963DFQ35633272-7426912D-A9EB-472E-90CE-38690EF45510Q35808372-591FA59D-831D-443F-B203-82696E53644FQ35906333-5E0EB0EF-2736-4CD7-901B-F1C5BA0AB3D3Q36178261-7EF04DEF-F7CE-465D-82AE-9442B9BDD59AQ36573827-CC74BDAD-40DD-4CD5-A292-D7B953C5B149Q36610578-57623084-F200-4B15-81B9-0F30919B62C5Q36696565-7A352877-7C71-4473-866E-022723652DB4Q36849977-46E4AA5D-5C1E-423E-8186-8F9552076AC1Q36925172-66DEC31B-5AE9-4D20-B5C4-404E8561D62EQ37119906-0ED31448-FB98-4C64-A0CA-A7043B7F0AACQ37219731-2F6DD172-2155-482C-8849-A1D2439765E7Q37268628-F2EA2571-7AE5-4291-88C6-B2268669E387Q37525906-42D4566A-B1AE-4416-97C9-8A3BD13E0028Q37632099-FE6773AD-646D-4D82-AEF2-F628BDAD5DAAQ37996438-09AB6435-9FEA-4059-9151-2885D8E28CBAQ38073703-13AC0259-9790-4740-B4AF-BB314036873EQ38242066-FF3D324F-8E5B-4364-8A5A-470A67FD45D6Q50629535-3951CB8B-6A61-4B27-96DF-7C428AFAA6ECQ51416016-0B6D0C72-696E-4075-85CA-40467BA05AA4Q51808027-0D52AA42-E028-44A2-AE94-2781DF322334Q57137351-33562EF0-8677-4F37-B2DB-93E2583E1CAA
P2860
Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@ast
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@en
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@nl
type
label
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@ast
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@en
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@nl
prefLabel
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@ast
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@en
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@nl
P2093
P50
P1476
Oral contraceptive use and ris ...... of BRCA1 and BRCA2 mutations.
@en
P2093
Alice S Whittemore
Dee W West
Frederick P Li
Margaret R E McCredie
Ronald Balbuena
P304
P356
10.1158/1055-9965.EPI-04-0376
P50
P577
2005-02-01T00:00:00Z